{"retracted":false,"update":{"timestamp":1486598400000,"doi":"10.1371/journal.pone.0172184","type":"correction"},"doi":"10.1371/journal.pone.0164455","journal":"PLOS ONE","publisher":"Public Library of Science (PLoS)","title":"Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study"}
